The impact of cisplat based chemotherapy on advanced ovarian cancer.
J Postgrad Med
;
1995 Oct-Dec; 41(4): 95-8
Artigo
em Inglês
| IMSEAR
| ID: sea-117060
ABSTRACT
Cisplatinum based chemotherapy has become the standard treatment for ovarian cancers due to its proved superiority over non-cisplat based regimes. However, the therapeutic impact of cisplat based regimes compared to cheaper non-cisplatinum based regimes is questionable when multiple variables such as residual disease, histologic type, grade are introduced. This report is a study of 110 Stage III ovarian cancer patients from 1985-89, with cisplat (n = 69) and non cisplat (n = 41) based chemotherapy. The results of both regimes with reference to the multiple variable factors are presented. We conclude that cisplat based regimes appear to be superior to non-cisplat based regimes except probably in poorly differentiated ovarian tumors where the results were similar with either regimen.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Assunto principal:
Neoplasias Ovarianas
/
Feminino
/
Humanos
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Doxorrubicina
/
Metotrexato
/
Taxa de Sobrevida
/
Cisplatino
/
Resultado do Tratamento
/
Ciclofosfamida
Idioma:
Inglês
Revista:
J Postgrad Med
Ano de publicação:
1995
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS